Cargando…

What matters most to patients with multiple myeloma? A Pan-European patient preference study

INTRODUCTION: Given the rapid increase in novel treatments for patients with multiple myeloma (MM), this patient preference study aimed to establish which treatment attributes matter most to MM patients and evaluate discrete choice experiment (DCE) and swing weighting (SW) as two elicitation methods...

Descripción completa

Detalles Bibliográficos
Autores principales:	Janssens, Rosanne, Lang, Tamika, Vallejo, Ana, Galinsky, Jayne, Morgan, Kate, Plate, Ananda, De Ronne, Chris, Verschueren, Margaux, Schoefs, Elise, Vanhellemont, Anneleen, Delforge, Michel, Schjesvold, Fredrik, Cabezudo, Elena, Vandebroek, Martina, Stevens, Hilde, Simoens, Steven, Huys, Isabelle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9745810/ https://www.ncbi.nlm.nih.gov/pubmed/36523996 http://dx.doi.org/10.3389/fonc.2022.1027353

Ejemplares similares

Patient Preferences for Multiple Myeloma Treatments: A Multinational Qualitative Study
por: Janssens, Rosanne, et al.
Publicado: (2021)

Selinexor, Bortezomib and Dexamethasone: An Effective Salvage Regimen for Heavily Pretreated Myeloma Patients
por: Delforge, Michel, et al.
Publicado: (2022)

What Does Society Value About Cancer Medicines? A Discrete Choice Experiment in the Belgian Population
por: Pauwels, Kim, et al.
Publicado: (2019)

Patient Involvement in the Lifecycle of Medicines According to Belgian Stakeholders: The Gap Between Theory and Practice
por: Janssens, Rosanne, et al.
Publicado: (2018)

What are the Unmet Needs and Most Relevant Treatment Outcomes According to Patients with Inflammatory Bowel Disease? A Qualitative Patient Preference Study
por: Schoefs, Elise, et al.
Publicado: (2022)

Opportunities and Challenges of Web-Based and Remotely Administered Surveys for Patient Preference Studies in a Vulnerable Population
por: Oliveri, Serena, et al.
Publicado: (2021)

How to balance valuable innovation with affordable access to medicines in Belgium?
por: Simoens, Steven, et al.
Publicado: (2022)

Key Determinants of Health-Related Quality of Life Among Advanced Lung Cancer Patients: A Qualitative Study in Belgium and Italy
por: Janssens, Rosanne, et al.
Publicado: (2021)

Quantifying benefit-risk preferences for new medicines in rare disease patients and caregivers
por: Morel, T., et al.
Publicado: (2016)

Opportunities and challenges for the inclusion of patient preferences in the medical product life cycle: a systematic review
por: Janssens, Rosanne, et al.
Publicado: (2019)

R&D Costs of New Medicines: A Landscape Analysis
por: Simoens, Steven, et al.
Publicado: (2021)

Emerging Insights into European Markets of Biologics, Including Biosimilars
por: Simoens, Steven, et al.
Publicado: (2022)

Current and Novel Alkylators in Multiple Myeloma
por: Schjesvold, Fredrik, et al.
Publicado: (2021)

How can patient preferences be used and communicated in the regulatory evaluation of medicinal products? Findings and recommendations from IMI PREFER and call to action
por: Janssens, Rosanne, et al.
Publicado: (2023)

Drug shortages in European countries: a trade-off between market attractiveness and cost containment?
por: Pauwels, Kim, et al.
Publicado: (2014)

Insights into European Drug Shortages: A Survey of Hospital Pharmacists
por: Pauwels, Kim, et al.
Publicado: (2015)

Industry Perspectives on Market Access of Innovative Drugs: The Relevance for Oncology Drugs
por: Pauwels, Kim, et al.
Publicado: (2016)

Methodological Quality Assessment of Budget Impact Analyses for Orphan Drugs: A Systematic Review
por: Abdallah, Khadidja, et al.
Publicado: (2021)

How to Value Orphan Drugs? A Review of European Value Assessment Frameworks
por: Blonda, Alessandra, et al.
Publicado: (2021)

HER2 is not a cancer subtype but rather a pan-cancer event and is highly enriched in AR-driven breast tumors
por: Daemen, Anneleen, et al.
Publicado: (2018)

Toward a European definition for a drug shortage: a qualitative study
por: De Weerdt, Elfi, et al.
Publicado: (2015)

Time Investment in Drug Supply Problems by Flemish Community Pharmacies
por: De Weerdt, Elfi, et al.
Publicado: (2017)

Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!
por: Dutta, Binita, et al.
Publicado: (2019)

European Stakeholder Learnings Regarding Biosimilars: Part II—Improving Biosimilar Use in Clinical Practice
por: Barbier, Liese, et al.
Publicado: (2020)

European Stakeholder Learnings Regarding Biosimilars: Part I—Improving Biosimilar Understanding and Adoption
por: Barbier, Liese, et al.
Publicado: (2020)

Use of Patient Preferences in Health Technology Assessment: Perspectives of Canadian, Belgian and German HTA Representatives
por: van Overbeeke, Eline, et al.
Publicado: (2020)

Patient Preferences in the Medical Product Life Cycle: What do Stakeholders Think? Semi-Structured Qualitative Interviews in Europe and the USA
por: Janssens, Rosanne, et al.
Publicado: (2019)

What Matters Most to Lung Cancer Patients? A Qualitative Study in Italy and Belgium to Investigate Patient Preferences
por: Petrocchi, Serena, et al.
Publicado: (2021)

Myeloma Patient Value Mapping: A Discrete Choice Experiment on Myeloma Treatment Preferences in the UK
por: Fifer, Simon, et al.
Publicado: (2020)

P-130: The impact of COVID-19 on the treatment regimens of myeloma and AL amyloidosis patients
por: Joyner, Katie, et al.
Publicado: (2021)

Managed Entry Agreements for Oncology Drugs: Lessons from the European Experience to Inform the Future
por: Pauwels, Kim, et al.
Publicado: (2017)

How Can We Optimize the Value Assessment and Appraisal of Orphan Drugs for Reimbursement Purposes? A Qualitative Interview Study Across European Countries
por: Blonda, Alessandra, et al.
Publicado: (2022)

Evaluating the benefits of TNF-alfa inhibitor biosimilar competition on off-patent and on-patent drug markets: A Southern European analysis
por: Barcina Lacosta, Teresa, et al.
Publicado: (2022)

An exploration of biosimilar TNF-alpha inhibitors uptake determinants in hospital environments in Italy, Portugal, and Spain
por: Barcina Lacosta, Teresa, et al.
Publicado: (2023)

Street vendors in Lima in the time of COVID‐19: Guilty or oppressed?
por: Coletto, Diego, et al.
Publicado: (2021)

Economic evaluation of biosimilars for reimbursement purposes – what, when, how?
por: Moorkens, Evelien, et al.
Publicado: (2020)

Barriers and Opportunities for Implementation of Outcome-Based Spread Payments for High-Cost, One-Shot Curative Therapies
por: Michelsen, Sissel, et al.
Publicado: (2020)

Applications of Behavioral Economics to Pharmaceutical Policymaking: A Scoping Review with Implications for Best-Value Biological Medicines
por: Vandenplas, Yannick, et al.
Publicado: (2022)

Biosimilar Use and Switching in Belgium: Avenues for Integrated Policymaking
por: Barbier, Liese, et al.
Publicado: (2022)

Comparison of [(18)F]fluciclovine and [(18)F]FDG PET/CT in Newly Diagnosed Multiple Myeloma Patients
por: Stokke, Caroline, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_hvtdphjc7gi3kgurmu6krl2le1